Drugs.com - Clinical Trials

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2025-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active...

Feb 9, 2025 - 21:44
 0
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2025-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active...
Read More

Tags:

Previous Article

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Pop...

Next Article

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial o...

Related Posts

FDA Grants Fast Track Designation to PleoPharma, Inc's Investigational New Drug, PP-01, for the Mitigation of Cannabis Withdrawal Symptoms in Patients With Cannabis Use Disorder

FDA Grants Fast Track Designation to PleoPharma, Inc's ...

Feb 17, 2025  0

AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Significant LDL Cholesterol (LDL-C) Reduction in PURSUIT Phase IIb Trial

AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Sig...

Apr 1, 2025  0

Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases with No Approved Medicines

Rilzabrutinib Granted Orphan Drug Designation in the US...

Apr 8, 2025  0